MX2016002589A - Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo. - Google Patents

Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo.

Info

Publication number
MX2016002589A
MX2016002589A MX2016002589A MX2016002589A MX2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A
Authority
MX
Mexico
Prior art keywords
fgfr4
pharmaceutical composition
fgf19
active ingredient
related cancer
Prior art date
Application number
MX2016002589A
Other languages
English (en)
Inventor
Takashi Futami
Rumi Takeshita
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016002589A publication Critical patent/MX2016002589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

Se proporciona una composición farmacéutica para el tratamiento de cáncer relacionado con FGFR4, cáncer relacionado con FGF19, o cáncer de hígado positivo para la amplificación del gen FGF19. Los presentes inventores han perfeccionado la presente invención a través del estudio de compuestos que tienen un efecto inhibitorio sobre FGFR4 verificando que los compuestos específicos de pirimidina tengan un efecto inhibitorio sobre FGFR4 y una composición farmacéutica que tiene estos compuestos como ingredientes activos que tienen un efecto terapéutico contra el cáncer relacionado con FGFR4 o en otra modalidad, cáncer relacionado con FGFI9 y aun en otra modalidad, cáncer de hígado positivo para la amplificación del gen FGF19.
MX2016002589A 2013-08-28 2014-08-27 Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo. MX2016002589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013176355 2013-08-28
PCT/JP2014/072349 WO2015030021A1 (ja) 2013-08-28 2014-08-27 ピリミジン化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
MX2016002589A true MX2016002589A (es) 2016-06-14

Family

ID=52586573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002589A MX2016002589A (es) 2013-08-28 2014-08-27 Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo.

Country Status (16)

Country Link
US (1) US20160199371A1 (es)
EP (1) EP3040072A4 (es)
JP (1) JPWO2015030021A1 (es)
KR (1) KR20160040719A (es)
CN (1) CN105492009A (es)
AR (1) AR097455A1 (es)
AU (1) AU2014312919A1 (es)
CA (1) CA2922352A1 (es)
HK (1) HK1219432A1 (es)
IL (1) IL244206A0 (es)
MX (1) MX2016002589A (es)
PH (1) PH12016500372A1 (es)
RU (1) RU2016106774A (es)
SG (1) SG11201601461RA (es)
TW (1) TW201605452A (es)
WO (1) WO2015030021A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
MY184733A (en) 2013-10-18 2021-04-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
EA028819B1 (ru) 2013-10-25 2018-01-31 Новартис Аг Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3283465B1 (en) 2015-04-14 2021-01-06 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN107541495B (zh) * 2016-06-28 2022-04-26 上海市东方医院 一种fgf19过表达的人肝癌细胞系及其应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
US11229643B2 (en) 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US20230172867A1 (en) * 2020-05-15 2023-06-08 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
US20070161645A1 (en) 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
WO2013133351A1 (ja) * 2012-03-08 2013-09-12 アステラス製薬株式会社 新規ｆｇｆｒ３融合体

Also Published As

Publication number Publication date
KR20160040719A (ko) 2016-04-14
SG11201601461RA (en) 2016-03-30
IL244206A0 (en) 2016-04-21
CN105492009A (zh) 2016-04-13
TW201605452A (zh) 2016-02-16
CA2922352A1 (en) 2015-03-05
HK1219432A1 (zh) 2017-04-07
RU2016106774A (ru) 2017-10-03
AU2014312919A1 (en) 2016-03-10
AR097455A1 (es) 2016-03-16
EP3040072A4 (en) 2017-03-29
EP3040072A1 (en) 2016-07-06
JPWO2015030021A1 (ja) 2017-03-02
PH12016500372A1 (en) 2016-05-02
WO2015030021A1 (ja) 2015-03-05
US20160199371A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
NZ748345A (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX357296B (es) Derivados piperidinopirimidinicos para el tratamiento de infecciones viricas.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IL228600B (en) (Aralkylamino and heteroarylalkylamino alpha-converted) pyrimidinyl and 1,3,5-triazinyl benzaimidazoles, pharmaceutical preparations containing them and use of these compounds in the treatment of proliferative diseases
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EP3539951A4 (en) NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.